VRCI.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 22:55):

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients...

Stats
今日成交量	5 227.00
平均成交量	383 928
市值	17.58M
EPS	£0 ( 2023-10-05 )
下一个收益日期	( £0 ) 2024-06-28
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.450
ATR14	£0.290 (4.08%)

Verici Dx plc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Verici Dx plc 财务报表

Annual	2022
营收:	£0
毛利润:	£0 (0.00 %)
EPS:	£-0.0690

FY	2022
营收:	£0
毛利润:	£0 (0.00 %)
EPS:	£-0.0690

FY	2021
营收:	£0.00
毛利润:	£0.00 (0.00 %)
EPS:	£-4.89

Financial Reports:

No articles found.

Verici Dx plc

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.